EUVIMEDEUVIMED entdecken
Crossref

Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications

Yang Wang, Lin Ma iD, Zijun Kuang, Dengke Li, Jian Yang iD, Yuxia Liu, Lan Zhang, Zheng Li iD, Qingnuan Li

Molecular Pharmaceutics · 05.08.2024 · 21 (8) · 3838-3847

DOI: 10.1021/acs.molpharmaceut.4c00122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.07.2024. Verfasst von Yang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. Hauptthemen laut MEDLINE: Claudins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Shanghai Vista Pharmaceutical Technology Co., Ltd., Shanghai Institute of Applied Physics, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin18.2 (CLDN18.2), due to its high expression in various gastric cancer tissues, is considered an optimal target for antitumor drug molecules. In this study, we obtained the labeled compounds of [125I]I-zolbetuximab using the Iodogen method. Under the optimum labeling conditions, the molar activity of [125I]I-zolbetuximab was 1.75 × 102 GBq/μmol, and the labeling efficiency was more than 99%. The labeled compounds exhibited excellent in vitro stability in both phosphate buffer saline (PBS, pH = 7.4) and fetal bovine serum systems (FBS) (radiochemical purity >90% at 72 h). The uptake percentage of [125I]I-zolbetuximab in MKN45-CLDN18.2 cells is 24.69 ± 0.84% after 6 h. The saturation binding assay and specificity assay further demonstrated the high specificity of [125I]I-zolbetuximab for CLDN18.2. The long retention at the tumor site and rapid metabolic clearance at other organ sites of [125I]I-zolbetuximab were observed in small-animal SPECT-CT imaging. The same trend was also observed in the biodistribution study. Due to the excellent targeting ability of zolbetuximab for CLDN18.2, [125I]I-zolbetuximab exhibits strong specific binding and retention with cells and tumors highly expressing CLDN18.2. However, the balance between mAb's longer cycle time in vivo and targeting binding and retention ability should be intensively considered for using this kind of radiopharmaceutical in the diagnosis and treatment of CLDN18.2-positive gastric cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClaudinsAnimalsHumansMiceTissue DistributionCell Line, TumorIodine RadioisotopesStomach NeoplasmsRadiopharmaceuticalsMice, NudeXenograft Model Antitumor AssaysMice, Inbred BALB CAntibodies, MonoclonalFemaleMaleRats

Stichwörter der Autor:innen

125ICLDN18.2biological evaluationgastric cancerzolbetuximab

Substanzen

CLDN18 protein, humanClaudinsIodine RadioisotopesRadiopharmaceuticalsAntibodies, MonoclonalIodine-125

Autor:innen und Institutionen

  • Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Shanghai Vista Pharmaceutical Technology Co., Ltd, Shanghai 201816, China.
  • Shanghai Engineering Research Center of Organ Repair, School of Medicine, Shanghai University, Shanghai 200444, China.

ORCID-Profile: Lin Ma, Jian Yang, Zheng Li

Förderung

  • Shanghai Vista Pharmaceutical Technology Co., Ltd.
  • Shanghai Institute of Applied Physics, Chinese Academy of Sciences

Zitieren

APA

Wang, Y., Ma, L., Kuang, Z., Li, D., Yang, J., Liu, Y., Zhang, L., Li, Z., & Li, Q. (2024). Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications. Molecular Pharmaceutics, 21(8), 3838-3847. https://doi.org/10.1021/acs.molpharmaceut.4c00122

Vancouver

Wang Y, Ma L, Kuang Z, Li D, Yang J, Liu Y, et al. Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications. Molecular Pharmaceutics. 2024;21(8):3838-3847. doi:10.1021/acs.molpharmaceut.4c00122

BibTeX
@article{Wang2024,
  author = {Wang, Yang and Ma, Lin and Kuang, Zijun and Li, Dengke and Yang, Jian and Liu, Yuxia and Zhang, Lan and Li, Zheng and Li, Qingnuan},
  title = {Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {8},
  pages = {3838--3847},
  doi = {10.1021/acs.molpharmaceut.4c00122}
}
Kostenlos starten →